Non-injection immunotherapy
AssigneeCuralogic, A/S
InventorsPeter Moldt, Ove Pedersen, Klaus Theobald, Michael Flanagan
Life of this patent
Estimating the term…
Abstract
Methods and compositions are disclosed for the reduction of immune responses to an exogenous allergen. The reduction is obtained by pre-treatment or pre-conditioning, without injection, of a subject with the allergen so as to reduce immune responses in the subject upon additional exposure to the allergen. The invention is advantageously used in a variety of contexts, including seasonal allergies wherein pre-treatment or pre-conditioning is performed before the onset of the seasonal allergy.
Claims26
A method of conditioning a subject to have reduced symptoms of allergic rhinitis or allergic conjunctivitis to an environmental allergen, said method comprising
- non-injection based administration of a composition comprising an allergen to said subject, such that said allergen is delivered to the small intestine, for a period of more than eight weeks prior to exposure of said subject to said allergen in the subject's environment,
- wherein said administration of said composition conditions said subject to have reduced symptoms of allergic rhinitis or allergic conjunctivitis to said environmental allergen.
A method of reducing a subject's immune response to an allergen, said method comprising
- oral based administration of a first composition comprising one or more allergens to said subject, such that said allergens are delivered to the small intestine, for a period of more than eight weeks prior to exposure of said subject to said allergen in the subject's environment, and
- maintaining oral administration of said one or more allergens by a second composition comprising said one or more allergens to said subject during said exposure of the subject to said allergen in the subject's environment,
- wherein said administrations of said first and second compositions reduces said subject's immune response to the allergen.
(canceled)
A plurality of doses for oral administration, said plurality of doses comprising individual compositions of increasing amounts, ranging from about 5 to about 40 units of one or more ragweed antigen.
Dependencies are inferred from the claim text.